ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,858.90
0.09%
S&P ASX All Technology
3,070.40
-0.24%
Brent Oil
82.175
-0.33%
US Dollar vs AUD
1.50015
0.01%
Bitcoin
69,309.78
-1.17%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Pyxis Oncology Inc (PYXS)

  7. Pyxis Oncology Inc (PYXS) News

PYXS

Pyxis Oncology (PYXS)

Pyxis Oncology Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:PYXS
DateTimeSourceHeadlineSymbolCompany
14/05/202422:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PYXSPyxis Oncology Inc
14/05/202421:55Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PYXSPyxis Oncology Inc
14/05/202421:30GlobeNewswire Inc.Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024NASDAQ:PYXSPyxis Oncology Inc
09/05/202421:30GlobeNewswire Inc.Pyxis Oncology to Present at the RBC Capital Markets Global Healthcare ConferenceNASDAQ:PYXSPyxis Oncology Inc
29/03/202407:30GlobeNewswire Inc.Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:PYXSPyxis Oncology Inc
27/03/202422:30GlobeNewswire Inc.Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty RightsNASDAQ:PYXSPyxis Oncology Inc
21/03/202422:30GlobeNewswire Inc.Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023NASDAQ:PYXSPyxis Oncology Inc
13/03/202423:00GlobeNewswire Inc.Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFANASDAQ:PYXSPyxis Oncology Inc
09/03/202408:03Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:PYXSPyxis Oncology Inc
08/03/202408:30GlobeNewswire Inc.Pyxis Oncology to Present at Leerink Global Biopharma Conference 2024NASDAQ:PYXSPyxis Oncology Inc
06/03/202408:45GlobeNewswire Inc.Pyxis Oncology to Present New PYX-201, PYX-106 and PYX-102 Preclinical Data at AACR Annual MeetingNASDAQ:PYXSPyxis Oncology Inc
28/02/202423:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PYXSPyxis Oncology Inc
28/02/202400:00GlobeNewswire Inc.Pyxis Oncology Announces $50 Million Private PlacementNASDAQ:PYXSPyxis Oncology Inc
30/12/202308:33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PYXSPyxis Oncology Inc
30/12/202308:30GlobeNewswire Inc.Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:PYXSPyxis Oncology Inc
07/12/202308:50Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:PYXSPyxis Oncology Inc
01/12/202308:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PYXSPyxis Oncology Inc
28/11/202323:22Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PYXSPyxis Oncology Inc
28/11/202323:00GlobeNewswire Inc.Pyxis Oncology Announces Appointment of Ken Kobayashi, M.D., F.A.C.P as Chief Medical OfficerNASDAQ:PYXSPyxis Oncology Inc
18/11/202308:16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PYXSPyxis Oncology Inc
08/11/202308:46Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PYXSPyxis Oncology Inc
08/11/202308:44Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PYXSPyxis Oncology Inc
08/11/202308:30GlobeNewswire Inc.Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter 2023 and Provides Corporate UpdateNASDAQ:PYXSPyxis Oncology Inc
28/10/202307:34Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:PYXSPyxis Oncology Inc
29/09/202306:32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PYXSPyxis Oncology Inc
28/09/202308:37Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PYXSPyxis Oncology Inc
28/09/202308:36Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PYXSPyxis Oncology Inc
27/09/202323:18GlobeNewswire Inc.Pyxis Oncology Announces Four Abstracts Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2023NASDAQ:PYXSPyxis Oncology Inc
26/09/202307:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PYXSPyxis Oncology Inc
26/09/202307:04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PYXSPyxis Oncology Inc
 Showing the most relevant articles for your search:NASDAQ:PYXS

Your Recent History

ASX
BHP
BHP
ASX
XMM
S&P ASX 300 Metals and M...
FX
AUDJPY
AUD vs Yen
ASX
FMG
Fortescue
NYSE
VZ
Verizon Communications
ASX
XFL
S&P ASX 50
NASDAQ
AAPL
Apple
ASX
ORG
Origin Energy
FX
AUDUSD
AUD vs US Dollar
ASX
XJO
S&P ASX 200
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NYSE
JPM
JP Morgan Chase
SPI
SP500
S&P 500
ASX
TLS
Telstra
NYSE
NKE
Nike
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved